Josh Jennings
Stock Analyst at Morgan Stanley
(2.64)
# 2,022
Out of 4,843 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $26.99 | +96.37% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $323.58 | -7.29% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $2.43 | +723.05% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $21.25 | +196.47% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.82 | +753.66% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $77.73 | -48.54% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $26.99
Upside: +96.37%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $323.58
Upside: -7.29%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $2.43
Upside: +723.05%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $21.25
Upside: +196.47%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.82
Upside: +753.66%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $77.73
Upside: -48.54%